Reuters logo
BRIEF-‍Palleon Pharmaceuticals raises $47.6 mln to develop glycoimmune checkpoint inhibitors
October 4, 2017 / 11:18 AM / 19 days ago

BRIEF-‍Palleon Pharmaceuticals raises $47.6 mln to develop glycoimmune checkpoint inhibitors

Oct 4 (Reuters) -

* ‍Palleon Pharmaceuticals raises $47.6 million to develop glycoimmune checkpoint inhibitors, a new class of medicines designed to overcome resistance to first-generation immuno-oncology drugs​ Source text for Eikon:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below